In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff.
Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are updated and new treatments become available, developing individualized treatment regimens is key and collaboration between clinician and patient and family is critical in optimizing patient outcomes. Clinicians should use measurement-based care to assess whether treatment changes are necessary, which requires engaging with the patient to monitor efficacy and manage side effects.
Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample of Veterans with varying disorders and behaviors.
In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.
Involving patients in designing their own treatment strategies according to their tolerability criteria can help combat the 90% nonadherence rate in patients being treated for bipolar disorder. Find out from experts about best practices in addressing patient concerns and balancing tolerability with efficacy and adherence in treating patients with bipolar disorder.
Adopting consensus guidelines while applying new evidence on the latest treatment options can often be a matter of balancing risks, benefits, and tolerability when addressing acute episodes in bipolar I disorder. Sit in on the discussion between three experts as they discuss guideline-directed treatment strategies that address manic and mixed episodes in patients with bipolar I disorder, and listen to one patient’s journey to hope and recovery.
Dr Goldberg describes the role of the clinician as that of a travel agent, asking the patient, “Where do you want to go; what do you want it to be like there; how do you want to get there;” etc, then providing the patient with the related evidence-supported information. Learn how to become your patients’ travel agent for their journey through optimizing treatment strategies for type I and type II bipolar disorder.
Treating bipolar I and bipolar II depression is not one-size-fits-all. Learn from field experts about practice guidelines, novel agents, and approaches to developing personalized treatment plans for patients with bipolar depression type I and type II.
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.
Drs Goldberg, Swartz, and DelBello discuss the spectrum of bipolar disorder, from major depressive disorder to bipolar I, and assessment strategies for establishing accurate diagnoses, including age, gender, signs and symptoms, and comorbidities to facilitate appropriate treatments and improve patient outcomes.


Subscribe to RSS - Bipolar Disorder